Chemed (CHE) CEO Kevin McNamara Sells 3,000 Shares at $461.28
Kevin J. McNamara, President, CEO and a director of Chemed Corporation (CHE), reported an open-market sale of 3,000 shares of Chemed common stock on 09/26/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kevin J. McNamara, President, CEO and a director of Chemed Corporation (CHE), reported an open-market sale of 3,000 shares of Chemed common stock on 09/26/2025. The reported weighted-average sale price was $461.28 per share (transactions ranged from $460.03 to $462.44). After the sale the reporting person beneficially owned 96,197 shares. The Form 4 includes an offer to provide transaction-level price/volume details on request.
Positive
- None.
Negative
- Insider disposition: CEO and director sold 3,000 shares on 09/26/2025, reducing beneficial ownership to 96,197 shares.
- Sale disclosed without context: Form 4 does not state percentage of total holdings sold or use of proceeds, limiting investors' ability to assess intent.
Insights
TL;DR: Insider sale of 3,000 shares at ~$461.28 reduces holdings to 96,197 shares; transaction appears routine and not materially transformative.
The Form 4 discloses a single open-market disposition by CEO Kevin McNamara totaling 3,000 shares at a reported weighted-average price of $461.28 on 09/26/2025. The filing notes multiple execution prices within a narrow range, implying standard block sale execution rather than an exercise-related transfer. The sale represents a specified number of shares but the filing provides no context on percentage of total holdings or intended use of proceeds. Absent additional firmsize-relative metrics, this is a routine disclosure rather than a material corporate development.
TL;DR: Director/CEO reported a small open-market sale; filing meets Section 16 disclosure requirements and includes explanatory footnote.
The submission satisfies Section 16 reporting by specifying the transaction date, quantity, weighted-average price and resulting beneficial ownership. Inclusion of a footnote offering granular trade details is good disclosure practice. There is no indication of related-party transactions or changes to control. From a governance perspective, the filing is compliant and transparent but provides limited information for assessing insider intent.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Capital Stock | 3,000 | $461.28 | $1.38M |
Footnotes (1)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $460.03 to $462.44. The reporting person undertakes to provide to Chemed Corporation, any security holder of Chemed Corporation, or staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) of this Form 4.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CHE insider Kevin J. McNamara report on Form 4?
What price range did the CHE sale occur at?
What is Kevin McNamara's role at CHE as reported on the form?
Does the Form 4 indicate any derivative transactions or amendments?
Can investors obtain more granular trade details from the filer?
AI-generated analysis. How Rhea-AI works. Not financial advice.